ETC 588

Drug Profile

ETC 588

Alternative Names: ESP-24228; ETC-588; Large unilamellar vesicles; LUV

Latest Information Update: 17 May 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Esperion Therapeutics
  • Class Phospholipids
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute coronary syndromes; Atherosclerosis

Most Recent Events

  • 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
  • 22 Oct 2003 Espirion has completed enrolment in the ETC 588-004 and ETC 588-005 trials
  • 10 Jun 2003 Esperion is pursuing a corporate agreement to co-promote and co-develop ETC 588 in North America []
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top